{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-22-007530","form_type":"8-K","ticker":"PHIO","cik":"0001533040","company_name":"Phio Pharmaceuticals Corp.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.051032+00:00","generated_at":"2026-06-21T22:54:57.441883+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Phio Q3 net loss $3.6M, cash $14.5M; appoints Bitterman, Mahoney, Spellman","bullets":["New appointments: Robert Bitterman as Interim Executive Chairman, Linda Mahoney as VP of Project Development, Dr. Mary Spellman as medical advisor.","Cash at Sept 30, 2022: $14.5M, down from $24.1M at Dec 31, 2021; expects to fund operations for at least 12 months.","Net loss $3.6M ($0.26/share) vs $3.7M ($0.28) in Q3 2021; R&D expenses down 6% to $2.5M.","Phase 1b study of PH-762 for advanced melanoma continues enrollment; top-line data expected Q1 2023.","Plans to initiate trial with AgonOx in Q4 2022; IND-enabling studies for PH-894 by year end."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-22-007530","json":"https://secwatch.observer/filing/0001683168-22-007530.json","markdown":"https://secwatch.observer/filing/0001683168-22-007530.md","text":"https://secwatch.observer/filing/0001683168-22-007530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/0001683168-22-007530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/phio_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:54:57.441883+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6a8cd4ce31d1ef2ff7eb32f0c2f188756dcec1f3","claim":"Phio Pharmaceuticals Corp. reported the quarter ended September 30, 2022 results: net income approximately $3.6 million, or $0.26 per share, EPS $0.26 per share.","evidence_excerpt":"Net loss decreased 4% to approximately $3.6 million, or $0.26 per share, for the quarter ended September 30, 2022, compared with $3.7 million, or $0.28 per share, for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/0001683168-22-007530-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"approximately $3.6 million, or $0.26 per share"},{"label":"EPS","value":"$0.26 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}